← Companies|Adamas (Supernus)
Ad

Adamas (Supernus)

Emeryville CAFounded 2000100 employees
Private CapbiotechAcquiredNeurology
Platform: Gocovri Amant
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
SovazumabADA-6097Phase 12RadioligandIL-13EZH2iNMOSDADPKD
TerazanubrutinibADA-4957Preclinical1ERTSMN2USP1iLGSHeart Failure
ADA-3632ADA-3632NDA/BLA1siRNABETTYK2iFSGSPompe
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)
2026-09-01
Sovazumab Interim
NMOSD
Interim
2027-05-01
Sovazumab Interim
Melanoma
Interim
2029-01-03
Terazanubrutinib Interim
RSV
Interim
2030-04-28
ADA-3632 Ph3 Readout
FSGS
Ph3 Readout